Key facts: GSK Increases Treasury Shares; Partners with AN2 on TB Drug; Announces Block Listing

TradingView
2025.11.13 01:03
portai
I'm PortAI, I can summarize articles.

On November 12, 2025, GSK plc bought 8,496,000 shares, increasing its treasury shares to 255,960,844, which is 6.31% of total voting rights.1AN2 Therapeutics collaborates with GSK to develop boron-based LeuRS inhibitors for tuberculosis, supported by a third year of funding from the Gates Foundation.2On November 12, 2025, GSK PLC announced its block listing six monthly return, detailing its compliance and engagement with the London Stock Exchange.3

  • On November 12, 2025, GSK plc bought 8,496,000 shares, increasing its treasury shares to 255,960,844, which is 6.31% of total voting rights.1
  • AN2 Therapeutics collaborates with GSK to develop boron-based LeuRS inhibitors for tuberculosis, supported by a third year of funding from the Gates Foundation.2
  • On November 12, 2025, GSK PLC announced its block listing six monthly return, detailing its compliance and engagement with the London Stock Exchange.3
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.